Milrinone Infusion for VAsospam Treatment in Subarachnoid hemoRrhage

Model scores of the 29,894 trials active now.

Model score 28% for any early termination, 11% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 8% of the time (53 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2026-01-12. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cthemorrhagecerebralinfusionintravenous
  Phrases that lowered it: adultstudy20administrationmmhg
• Sponsor's past termination rate: 13.9% (raises risk) · Sponsor's track record
• Design: factorial (lowers risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Drug's FAERS reports with a death: 36.6% (raises risk) · Drug's FDA history
• Phase: 3 (lowers risk) · Design
• Blinding: triple (raises risk) · Design
• Drug's FAERS reports marked serious: 94.9% (raises risk) · Drug's FDA history
• Has a data monitoring committee: Yes (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Trials the sponsor started in the prior 2 years: 41 (lowers risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Sponsor's past trials: 72 (raises risk) · Sponsor's track record
• Drug's FAERS reports in the prior 12 months: 147 (raises risk) · Drug's FDA history
• Drug's FAERS reports before start: 1509 (raises risk) · Drug's FDA history
• Collaborators: 0 (raises risk) · Design
• Number of arms: 2 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Milrinone in Addition to Hyperdynamic Therapy in the Treatment of Vasospasm Following Aneurysmal Subarachnoid Hemorrhage NCT02712788 · started 2016 · scored riskier than 97% of active trials terminated
• Management of Cerebral Vascular Spasm in Posttraumatic Subarachnoid Hemorrhage Using Combination Therapy NCT05131867 · started 2021 · scored riskier than 14% of active trials completed
• Effects of Prostacyclin Infusion on Cerebral Vessels and Metabolism in Patients With Subarachnoid Haemorrhage NCT01447095 · started 2011 · scored riskier than 63% of active trials completed
• Levosimendan as Treatment of Aneurysmal SubArachnoid Haemorrhage NCT05664191 · started 2023 · scored riskier than 95% of active trials completed
• Safety and Effect of SANGUINATE™ Infusion in Patients at Risk of Delayed Cerebral Ischemia (DCI) Following Subarachnoid Hemorrhage (SAH) NCT02323685 · started 2014 · scored riskier than 88% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.